|
Search the Site:
|
Program PartnersThe GARDASIL Access Program is made possible by a pledge from Merck & Co Inc., [Whitehouse Station, New Jersey, U.S.A.] and overseen by Axios Healthcare Development (AHD), a US non-profit organization. AHD administers the donation program, reviews and approves applications, and ensures prompt delivery of the vaccine to the recipients, with the technical assistance of Axios International, a public health consultancy specializing in developing and emerging countries. Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com Axios Healthcare Development (AHD) is a 501(C)(3) Public charity incorporated in the state of Delaware USA focused on the in-country implementation of philanthropic healthcare programs. Axios International is a consultancy founded in 1997 that specializes in strategic advice and technical assistance to improve access to healthcare in low and middle income countries. Axios is an organization dedicated to increasing access to treatment and care in developing countries through program strategy, design, implementation, research, evaluation, and communications. |
Eligibility Criteria
Find out if your organization or institution is eligible to apply for the program ![]() Eligible Countries
Organizations and institutions in these countries are invited to submit an application form. ![]() |